Related Experiment Video
Updated: May 16, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon-Like Peptide 1
Shanal Kumar1,2, Robyn Cobb1,3, Angela Matson1,4
1The Adult Cystic Fibrosis Centre (ACFC), the Prince Charles Hospital, Chermside Queensland Chermside Australia.
Abstract:
Cystic fibrosis (CF) modulator therapies can lead to rapid and excessive weight gain. Obesity in CF can lead to undesirable metabolic complications including type 2 diabetes. Therefore, glucagon-like peptide 1 (GLP-1) agonists which can facilitate weight loss and improve metabolic profiles are increasingly prescribed to people with CF. We present the first case report documenting serial changes in body composition and bone mineral density over a 3-year period in an adult with CF, obesity and diabetes treated with Semaglutide and Elexacaftor/Tezacaftor/Ivacaftor (ETI). Our case experienced substantial weight gain following ETI initiation which exacerbated hyperglycaemia. This prompted initiation of Semaglutide, which over 12 months led to 14.8% total body weight loss and significant glycaemic improvement. However, serial assessments revealed declines in absolute muscle mass, muscle strength and bone mineral density despite prescription of tailored exercise and nutritional interventions. Our findings highlight the need for cautious use of GLP-1 in people with CF.
More Related Videos
12:59Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
08:03Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
Related Concept Videos
Ethics in Research
The Stanford Prison Experiment
Bullying
Sex Linked Disorders
Sexually Transmitted Infections
Conduct Disorder